Changes in the activity of an enhancer on 20q13.33 led to abnormal expression of multiple genes associated with glioma risk (e.g., RTEL1, RTEL1-TNFRSF6B, SRMS and GMEB2) [36]. The gene discussed is SRMS; the disease is central nervous system cancer.